Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
Business Wire•30/10/2026•07:00 ET
0
Key Highlights
- ➤Alkermes initiated a phase 2 study of ALKS 7290 in adjunctive MDD treatment
- ➤Study will enroll approximately 180 adults with MDD, with or without excessive daytime sleepiness
- ➤Participants receive ALKS 7290 or placebo alongside antidepressants for six weeks
- ➤Primary objective evaluates ALKS 7290 safety and tolerability
- ➤ALKS 7290 is also in phase 2 development for adult ADHD
Expert Statements
Craig Hopkinson, Chief Medical Officer and Executive Vice President of Research & Development at Alkermes
“Orexin biology represents a compelling area of scientific exploration in neuropsychiatry, given its central role in regulating wakefulness and its broad connections to neural circuits relevant to attention, cognition and mood. Through this phase 2, proof-of-concept study, we aim to assess whether activation of the orexin system may offer a novel approach to addressing symptoms of major depressive disorder.”
Craig Hopkinson, Chief Medical Officer and Executive Vice President of Research & Development at Alkermes
“The initiation of this study marks another important milestone in the rapid advancement of our portfolio of orexin 2 receptor agonists and reflects our commitment to maintaining a leadership position in the development of orexin-based therapies across multiple neuropsychiatric indications.”
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
— Proof-of-Concept Study to Evaluate Effects of Orexin 2 Receptor Agonist on Symptoms of Depression in Adults With and Without Excessive Daytime Sleepiness —
Get started
Create a free account to read the full story.